PT2789348T - Lipossomas e método de produção correspondente - Google Patents

Lipossomas e método de produção correspondente

Info

Publication number
PT2789348T
PT2789348T PT128230950T PT12823095T PT2789348T PT 2789348 T PT2789348 T PT 2789348T PT 128230950 T PT128230950 T PT 128230950T PT 12823095 T PT12823095 T PT 12823095T PT 2789348 T PT2789348 T PT 2789348T
Authority
PT
Portugal
Prior art keywords
liposomes
production method
corresponding production
production
Prior art date
Application number
PT128230950T
Other languages
English (en)
Original Assignee
Univ Do Minho
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Do Minho filed Critical Univ Do Minho
Publication of PT2789348T publication Critical patent/PT2789348T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT128230950T 2011-12-07 2012-12-07 Lipossomas e método de produção correspondente PT2789348T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT10605011 2011-12-07

Publications (1)

Publication Number Publication Date
PT2789348T true PT2789348T (pt) 2021-11-11

Family

ID=47681975

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128230950T PT2789348T (pt) 2011-12-07 2012-12-07 Lipossomas e método de produção correspondente

Country Status (5)

Country Link
US (1) US9393320B2 (pt)
EP (1) EP2789348B1 (pt)
CA (1) CA2858741C (pt)
PT (1) PT2789348T (pt)
WO (1) WO2013084208A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3188724B1 (en) * 2014-08-14 2021-11-10 L.E.A.F Holdings Group LLC Liposome encapsulated affinity drug
EP3158992A1 (en) * 2015-10-21 2017-04-26 Universität Heidelberg Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
WO2017105344A1 (en) * 2015-12-17 2017-06-22 Nanyang Technological University Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them
CN110548152A (zh) * 2018-05-30 2019-12-10 复旦大学 一种穿膜抗炎肽修饰的肿瘤靶向多药共载脂质体及其制备方法
BR112021022182A2 (pt) 2019-05-07 2021-12-21 Univ Do Minho Método para produção de lipossomas.
WO2020240445A1 (en) * 2019-05-27 2020-12-03 Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec - Associação Phosphatidylcholine liposomes for use in autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
IL143555A0 (en) 1998-12-18 2002-04-21 Hadasit Med Res Service Method of administering a compound to multi-drug resistant cells
CA2503094A1 (en) 2002-02-27 2003-09-04 The Ohio State University Research Foundation Therapeutic methods for acute myeloid leukemia
US20050191344A1 (en) 2004-01-15 2005-09-01 Samuel Zalipsky Liposome composition for delivery of therapeutic agents
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
WO2007139815A2 (en) 2006-05-23 2007-12-06 Purdue Research Foundation Imaging and therapeutic method using progenitor cells
GR1006666B (el) 2006-07-21 2010-01-19 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος" Μοριακοι δενδριτικοι φορεις με προσαρμοζομενη/μεταβαλλομενη διαλυτοτητα και συμπληρωματικοτητα προς μεμβρανικους υποδοχεις
CN101684177A (zh) 2009-05-27 2010-03-31 沈阳药科大学 叶酸偶联聚乙二醇聚烷基氰基丙烯酸酯及制法和应用
US20120100206A1 (en) 2009-06-11 2012-04-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof

Also Published As

Publication number Publication date
US9393320B2 (en) 2016-07-19
EP2789348A2 (en) 2014-10-15
EP2789348B1 (en) 2021-08-04
WO2013084208A3 (pt) 2013-11-07
CA2858741C (en) 2018-07-31
US20140335164A1 (en) 2014-11-13
CA2858741A1 (en) 2013-06-13
WO2013084208A2 (pt) 2013-06-13

Similar Documents

Publication Publication Date Title
EP2722540A4 (en) STABILIZATION COMPOUND AND METHOD OF MANUFACTURING THEREOF
EP2671640A4 (en) COMPOSITION CONTAINING COPPER AND TITANIUM AND METHOD FOR PRODUCING THE SAME
IL230394A (en) Machine and method of making beverage
GB201107863D0 (en) Method and product
EP2683040A4 (en) BUSBAR KIT AND MANUFACTURING METHOD THEREFOR
EP2730914A4 (en) PROCESS FOR PRODUCTION OF PREPREG
EP2716952A4 (en) CONNECTION, AND METHOD OF MANUFACTURING THE SAME
EP2728213A4 (en) TELESCOPIC SHAFT AND MANUFACTURING METHOD THEREFOR
EP2775487A4 (en) REACTOR AND METHOD FOR PRODUCING THE SAME
HUE052131T2 (hu) Dohánytermesztési módszer
EP2913831A4 (en) PROCESS FOR PRODUCING RARE EARTH MAGNET
GB201113610D0 (en) Product and method
EP2737496A4 (en) ELECTRODE STRUCTURE AND METHOD FOR PRODUCING AN ELECTRODE
GB201116248D0 (en) Liposome production using isopropanol
EP2716970A4 (en) WASTE MELTING PROCESS
EP2722159A4 (en) STRUCTURE AND MANUFACTURING METHOD THEREFOR
EP2769013A4 (en) DEVICE AND METHOD FOR MANAGING THE CONCEPTION AND PRODUCING AN EMBROIDERED WORK
GB201118985D0 (en) Product and method
PT2760619T (pt) Método para produzir uma estrutura
ZA201308690B (en) Axle and production method
SG10201604976RA (en) Hydroxy-aminopolymers and method for producing same
EP2636771A4 (en) CRYSTAL METHOD
PT2789348T (pt) Lipossomas e método de produção correspondente
EP2800398A4 (en) SPEAKER AND METHOD FOR MANUFACTURING SAME
EP2698159A4 (en) PITAVASTATE-CONTAINING PREPARATION AND METHOD OF MANUFACTURING THEREOF